Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company based in South San Francisco, California. Founded in 1997, the company focuses on discovering, developing, and commercializing therapies that target muscle function. Its expertise lies in creating muscle activators and inhibitors to treat conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). Cytokinetics has developed a strong pipeline of therapies, including Omecamtiv Mecarbil, a cardiac muscle activator for heart failure, and Aficamten, a cardiac myosin inhibitor approved in 2024 for hypertrophic cardiomyopathy. The company also works on investigational therapies like RCA for heart failure and CK-307 for neuromuscular diseases. With a commitment to research and strategic partnerships, Cytokinetics aims to enhance patient access to innovative treatments and improve health outcomes for those with muscle-related diseases.